

MyProstateScore 2.0

Next Generation of Prostate Cancer Risk Assessment





Comprehensive Array of Biomarkers

MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer (Grade Group ≥2 or Gleason score ≥7) by analyzing a comprehensive array of 18 unique gene transcripts. Among the transcripts, the test's foundation is the novel gene fusion, T2:ERG.

T2:ERG is an oncogenic fusion that results in androgen-driven cell proliferation, and is present in most men with prostate cancer. There is no biomarker more specific for prostate cancer.

By combining the specificity of the T2:ERG gene fusion with a supporting array of 17 other genetic biomarkers that characterize prostate cancer, MyProstateScore 2.0 represents the next generation in prostate cancer risk prediction.

Flexible Algorithmic Analysis

The MPS2 algorithm has been developed to optimize diagnostic accuracy and provide clinical flexibility. For biopsy naïve men, MPS2 may be run as a standalone biomarker test or in the context of clinical factors. For men with a prior negative biopsy, certain clinical factors are required.

18 Biomarkers

T2:ERG SCHLAP1 OR51E2 APOC1 PCAT14 CAMKK2 PCA3 NKAIN1 B3GNT6



TFF3
SPON2
PCGEM1
TRGV9
TMSB15A
ERG
KLK3
KLK4
HOXC6

Risk Assessment Factors

Clinical factors that may be included in the MPS2 algorithm to complement biomarker analysis are:

















Best-in-Class Accuracy

The comprehensive array of biomarkers, robust analytical model, and clinical factor flexibility combine to create a test with best-in-class accuracy.

The accuracy of MPS2 is further tailored to specific patient cohorts through separate validation in biopsy naïve men and men with a prior negative biopsy.

When to Use MPS2

No previous biopsy

- Age 45-75: PSA 3-10 ng/mL
- Age >75: PSA 4-10 ng/mL
- If PSA is below threshold, then very suspicious DRE qualifies

Previous negative biopsy

- Age 45-75: PSA ≥3 ng/mL
- Age >75: PSA <u>></u>4 ng/mL
- If PSA is below threshold, then very suspicious DRE qualifies

Biopsy Naïve Men


95% NPV

Biopsy Naïve men with a Low Risk MPS2 result have a 95% probability that their biopsy will be negative for clinically significant prostate cancer (Gleason score \geq 7 or Grade Group \geq 2).

Men with a Prior Negative Biopsy

99% NPV

Prior Negative men with a Low Risk MPS2 result have a 99% probability that their biopsy will be negative for clinically significant prostate cancer (Gleason score \geq 7 or Grade Group \geq 2).



Risk category: Low or Elevated

Likelihood of Clinically Significant Cancer
Grade Group 2 or higher: 0-100%

Easy-to-Interpret Results

MPS2 results are available within 5-7 days and report the percent likelihood that clinically significant prostate cancer would be detected on biopsy. The cutoff for low risk is dependent on prior biopsy status.

7.5% Threshold for biopsy naïve patients

5.4% Threshold for prior negative patients

Reimbursement Support

LynxDx is committed to helping patients access our testing services. If your patients need help navigating coverage plans and policies with Medicare, Medicaid, commercial insurance plans, cash pay options, HSAs and FSAs, HMOs and PPOs, our team is here to help.



Questions?

1-888-978-8MPS

or email us at clientservices@lynxdx.com

How to Order MyProstateScore 2.0



Contact

the LynxDx team at 1-888-978-8MPS or clientservices@lynxdx.com to have a Client Services representative provide you with the materials and information needed to get started.



Collect

post-DRE urine sample as indicated in the MPS2 specimen collection guide.



Complete

the Test Requisition Form and ship patient specimen to LynxDx.

Contact Us

LynxDx is committed to providing exceptional service for you and your patients. If you have questions or need assistance, our team is here to help.

Phone: 1-888-978-8677 / 1-888-978-8MPS

Email: clientservices@lynxdx.com | www.lynxdx.com













